ArticleBone marrow transplantation2007
Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis.
Article in Bone marrow transplantation, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Stem cell transplantation for systemic sclerosis.The Cochrane database of systematic reviews · 2022Pooled it
- Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation.Bone marrow transplantation · 2012Guideline
- Corticosteroids and the risk of scleroderma renal crisis: a systematic review.Rheumatology international · 2012Pooled it
- CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I/II clinical trial conducted in Japan.Arthritis research & therapy · 2019Trial
- Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?Bone marrow transplantation · 2016Trial
- Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG.Bone marrow transplantation · 2010Trial
- Short-term cardiotoxicity and early echocardiographic changes following autologous hematopoietic stem cell transplantation: a single-center retrospective analysis.Frontiers in cardiovascular medicine · 2026Article
- Utilization of Stem Cells in Medicine: A Narrative Review.International journal of molecular sciences · 2025Review
- Stem cell therapy in systemic sclerosis.Clinical rheumatology · 2025Review
- Review
- Stem cell-based therapy for systemic sclerosis.Rheumatology advances in practice · 2023Review
- Long-Term Health Effects of Curative Therapies on Heart, Lungs, and Kidneys for Individuals with Sickle Cell Disease Compared to Those with Hematologic Malignancies.Journal of clinical medicine · 2022Review
- Reconstitution of the immune system and clinical correlates after stem cell transplantation for systemic sclerosis.Frontiers in immunology · 2022Review
- Re-evaluating inclusion criteria for autologous hematopoietic stem cell transplantation in advanced systemic sclerosis: Three successful cases and review of the literature.Journal of scleroderma and related disorders · 2021Article
- Life after Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis.Journal of blood medicine · 2021Review
- Application of stem cell transplantation in autoimmune diseases.Current opinion in hematology · 2019Review
- Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018Review
- Article
- Points to consider in renal involvement in systemic sclerosis.Rheumatology (Oxford, England) · 2017Review
- Stem cell autograft and allograft in autoimmune diseases.Clinical and experimental medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autologous hematopoietic stem cell transplantation (HSCT) utilizing a myeloablative regimen containing total body irradiation has been performed in patients with systemic sclerosis (SSc), but with substantial toxicity. We, therefore, conducted a phase I non-myeloablative autologous HSCT study in 10 patients with SSc and poor prognostic features. PBSC were mobilized with CY and G-CSF. The PBSC graft was cryopreserved without manipulation and re-infused after the patient was treated with a non-myeloablative conditioning regimen of 200 mg/kg CY and 7.5 mg/kg rabbit antithymocyte globulin. There was a statistically significant improvement of modified Rodnan skin score whereas cardiac (ejection fraction, pulmonary arterial pressure), pulmonary function (DLCO) and renal function (creatinine) remained stable without significant change. One patient with advanced disease died 2 years after the transplant from progressive disease. After median follow-up of 25.5 months, the overall and progression-free survival rates are 90 and 70% respectively. Autologous HSCT utilizing a non-myeloablative conditioning regimen appears to result in improved skin flexibility similar to a myeloablative TBI containing regimen, but without the toxicity and risks associated with TBI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.